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Purpose: This study was conducted to determine COPD severity at the time of diagnosis as 
confirmed by spirometry in patients treated in a US managed care setting.
Patients and methods: All patients with one or more inpatient stays, one or more emergency 
department visits, or two or more outpatient visits with diagnosis codes for COPD during 
1994–2006 were identified from the Lovelace Patient Database. From this group, a subset of 
continuously enrolled patients with evidence in claims of a first available pulmonary function 
test or pulmonary clinic visit and a confirmatory claim for a COPD diagnosis was selected. 
Medical chart abstraction was undertaken for this subset to gather information for diagnosis 
and severity staging of each patient based on the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) criteria for COPD.
Results: Of the 12,491 patients with a primary or secondary COPD diagnosis between 1994 
and 2006, there were 1520 continuously enrolled patients who comprised the study cohort. 
Among the 648 eligible records from patients with evidence of a pulmonary function test, 366 
were identified by spirometry as having COPD of GOLD stage I or higher (average percentage 
of predicted forced expiratory volume in 1 second: 60%): 19% were diagnosed at the stage of 
mild disease (GOLD stage I); 50% at moderate disease (GOLD stage II); and 31% at severe 
or very severe disease (GOLD stage III or IV , respectively). The majority of patients in these 
groups were not receiving maintenance treatment.
Conclusion: The results demonstrate a very low incidence of early-stage diagnosis, confirmed 
by a pulmonary function test, of COPD in a large US sample and support calls for increased 
screening for COPD and treatment upon diagnosis.
Keywords: lung function, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
detection, early treatment
Introduction
COPD is characterized by chronic airflow limitation caused by inflammation-mediated 
damage to lung tissue that is not fully reversible.1 COPD follows a slowly   progressive 
course whereby increasing airflow limitation impairs the general health and functional 
ability of the patient. While the course of COPD has historically been viewed as 
refractory to therapeutic intervention, recent studies suggest that the course of COPD 
can be modified.2–10 For example, smoking cessation can slow the rate of decline 
in lung function and improve survival.6 Furthermore, in large, randomized trials, 
  pharmacotherapeutic intervention has been associated with sustained improvement in 
symptoms, exercise capacity, and overall health status and reductions in the   frequency 
of exacerbations and the rate of decline of lung function.7–11 On the basis of these International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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data and others, the 2009 update of the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guidelines 
characterizes COPD as a treatable disease and states that 
“early diagnosis and implementation of treatment … have 
been demonstrated to prevent or delay the onset of airflow 
limitation or reduce its progression.”1
As in other chronic diseases, early diagnosis in its 
course and early intervention, when symptoms are mild, 
are thought to be critical for maximizing the probability of 
good therapeutic outcomes in COPD.5 While previous clinical 
trials of pharmacotherapeutic intervention have primarily 
been conducted in patients with severe or very severe disease, 
significant benefits have also been documented in patients with 
milder disease. In a recently published, prespecified subgroup 
analysis of data from the randomized, double-blind, placebo-
controlled UPLIFT (Understanding Potential Long-Term 
Impacts on Function with Tiotropium) trial, pharmacotherapy 
compared with placebo significantly reduced the rate of 
decline of post-bronchodilator forced expiratory volume in 
1 second (FEV1), improved health status, and prolonged the 
time to first exacerbation and to exacerbation resulting in 
hospitalization over 4 years in patients with GOLD stage II 
(moderate) disease.10 Similarly, in a post hoc analysis of data 
from the randomized, double-blind, placebo-controlled TORCH 
(Towards a Revolution in COPD Health) trial, pharmacotherapy 
compared with placebo significantly reduced moderate to severe 
exacerbations and improved health status and FEV1 in patients 
with GOLD stage II (moderate) disease.12
Approximately half of patients who suffer from COPD 
remain undiagnosed,12 and only 30%–50% of newly diagnosed 
patients have their diagnosis confirmed by spirometry.13 
Expert opinion suggests that most COPD patients are not 
diagnosed until advanced stages of the disease – that early 
disease, in particular, often goes unrecognized because it is 
manifested by mild and often subtle signs and symptoms.2,13 
However, severity at the time of diagnosis has not been sys-
tematically evaluated in epidemiologic research. This study 
was conducted to determine COPD severity at the time of 
initial spirometry-confirmed COPD diagnosis in a large 
sample of patients in the Lovelace Health Plan.
Material and methods
Data source
With institutional review board approval, data were obtained 
from the Lovelace Patient Database, a longitudinal, managed 
care data repository that includes information on demographics, 
enrollment, inpatient and outpatient claims, pharmacy fills, and 
clinical laboratory values for a managed care population in New 
Mexico of approximately 250,000 members (Lovelace Health 
System/Lovelace Health Plan, a staff- and network-model health 
maintenance organization [HMO]). The database currently 
contains approximately 13 years of health care data that are 
cross-linked in relational files so that complete episodes of care 
and longitudinal data for cases/controls, cohorts, and broader 
populations are available for research. Staff responsible for main-
taining and administering the database communicate regularly 
with clinicians, medical coders, and medical record specialists to 
help ensure that data used for research are interpreted correctly 
and to gain insight into organizational norms, physician practice 
patterns, coding practices, and data validity.
sample selection and severity staging
All patients with one or more inpatient stays, one or more 
emergency department visits, or two or more outpatient 
visits with diagnosis codes for COPD (ie, primary or 
secondary diagnosis of COPD defined using Interna-
tional Classification of Disease, Ninth Revision, Clinical 
Modification [ICD-9-CM] codes 491.x, 492.x, 496.x) 
from 1994 through 2006 were identified from the Lovelace 
Patient Database (Figure 1). From this group, a subset of 
continuously enrolled patients with evidence in claims of an 
initial pulmonary function test or a pulmonary clinic visit 
(using procedural codes) was selected. For these patients 
with one or more instances of a COPD diagnosis code in 
claims as well as evidence of spirometry in claims, the initial 
pulmonary function test date was considered the index date 
at which COPD diagnosis was confirmed using objective 
clinical data. Some of these patients may have had a COPD-
coded medical claim preceding the initial pulmonary func-
tion test. However, because the objective of the study was to 
ascertain COPD severity at the first objectively confirmed 
COPD diagnosis, the initial pulmonary function test date 
was considered the COPD diagnosis index date. Medical 
chart abstraction was undertaken for this subset of patients 
to gather information sufficient to permit “diagnosis” and 
severity staging of each patient based on the GOLD criteria 
for COPD (Table 1).1 Information gathered from the pulmo-
nary clinic charts included pulmonary function test values, 
smoking history, height, and weight. The clinic visit chart 
entries for abstraction were selected by targeting the two 
most recent visits prior to the COPD-coded encounter in 
the claims data. Post-bronchodilator spirometry was used 
in defining severity stages from medical charts.
The frequencies of asthma, cardiovascular disease, and 
depression – comorbidities commonly associated with COPD1 – 
were assessed as a function of COPD severity. Comorbidity International Journal of COPD 2011:6
Lovelace patient database (~250,000 members per year)
With ≥1 inpatient, ≥1 emergency department, or ≥2 outpatient encounters
having primary or secondary COPD diagnosis from 1994 through 2006
12,491 patients
Without a COPD diagnosis in the prior year and
with evidence in claims of pulmonary function tests or pulmonary clinic visits
1520 patients
Identified through pulmonary chart review as having pulmonary function test results
648 patients
With COPD of GOLD stage I or higher
366 patients
GOLD stage I
71 patients (19%)
GOLD stage II
189 patients (50%)
GOLD stage III
96 patients (26%)
GOLD stage IV
19 patients (5%)
Figure 1 sample selection and incident COPD cases.
Abbreviation: gOLD, global Initiative for Chronic Obstructive Lung Disease.
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was considered to be present if one or more medical claims 
for the relevant diagnosis code were identified during the year 
after the initial pulmonary function test. The frequency of 
prescription of COPD-related pharmacotherapy as a function 
of COPD severity was determined at diagnosis as well as after 
the pulmonary function test date by identifying pharmacy 
claims for oral corticosteroids or antibiotics, any maintenance 
treatment, or rescue medication. Maintenance treatment 
included anticholinergics, inhaled corticosteroids, long-acting 
beta agonists, or the combination of an inhaled corticosteroid 
and a long-acting beta agonist. Inhaled corticosteroids included 
flunisolide, mometasone, triamcinolone, beclomethasone, 
budesonide, dexamethasone, and fluticasone propionate. 
Long-acting beta agonists included formoterol and salmeterol. 
Rescue therapy included was albuterol. These pharmacy claims 
were extracted from the Lovelace claims database on or after 
the initial pulmonary function test date.
Data were summarized with descriptive statistics. No 
hypothesis testing was undertaken. GOLD stage III (severe) 
and IV (very severe) categories were collapsed for the 
  summaries of frequencies of comorbidities and COPD-
related medications by COPD severity.
Table 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for classification of COPD1
GOLD stage Descriptor Signs and symptoms Spirometry results based on  
post-bronchodilator FEV1
I Mild Mildly reduced airflow; sometimes a chronic  
cough and sputum production
FeV1/FVC , 70 
FeV1 $ 80% predicted
II Moderate Worsening airflow; shortness of breath typically  
brought on by exertion
FeV1/FVC , 70 
50% # FeV1 , 80% predicted
III severe Further worsening airflow; greater shortness  
of breath; reduced quality of life
FeV1/FVC , 70 
30% # FeV1 , 50% predicted
IV Very severe Severe reduction of airflow; chronic respiratory  
failure; greatly reduced quality of life
FeV1/FVC , 70 
FeV1 , 30% predicted or FeV1 , 50% 
predicted plus chronic respiratory failure
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.International Journal of COPD 2011:6
26%
5% 19%
50%
GOLD I
GOLD II
GOLD III
GOLD IV
Figure 2 COPD severity at initial spirometry-confirmed diagnosis in patients with 
COPD of global Initiative for Chronic Obstructive Lung Disease (gOLD) stage I 
or higher (n = 366).
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Results
sample
Figure 1 shows the derivation of the study sample. The 
Lovelace Patient Database showed 12,491 patients had one 
or more inpatient, one or more emergency department, or two 
or more outpatient encounters with a primary or secondary 
COPD diagnosis (ICD-9-CM codes 491.x, 492.x, 496.x) 
between 1994 and 2006. Of those 12,491 patients, there were 
1520 continuously enrolled patients with evidence of either 
a pulmonary function test or a pulmonary clinic visit who 
comprised the study cohort. Pulmonary function test results 
and other data necessary for ascertaining GOLD status were 
available from charts for 648 of these 1520 patients; charts 
for the remainder were not available because of issues with 
archiving and off-site storage. Of the 648 patients for whom 
pulmonary function test results were available, 366 were 
classified at their initial pulmonary clinic spirometry 
assessment as having confirmed COPD of GOLD stage I or 
higher (Figures 1 and 2). The overall average percentage of 
predicted FEV1 (post-bronchodilator) at the initial pulmo-
nary function test was 60% for these 366 patients.
Among the 648 patients for whom pulmonary function 
test results were available, 273 (42%) had a COPD encounter 
in the pre-index year. The majority (approximately 90%) of 
COPD medical claims for these 648 patients were associated 
with a physician office visit, as opposed to an emergency 
department visit or hospitalization.
Among the 366 patients with spirometry-confirmed 
COPD of GOLD stage I or higher at their initial pulmonary 
clinic spirometry assessment, 279 (76.2%) had a COPD 
diagnosis-coded encounter at some time prior to their 
  pulmonary function test; 41% had a COPD diagnosis-coded 
encounter in the year prior to the pulmonary function test. 
Only 25% of the 366 patients with spirometry-confirmed 
COPD of GOLD stage I or higher were initially diagnosed at 
pulmonary specialist offices; primary care settings accounted 
for the majority of the diagnosis claims.
severity of incident COPD cases at initial 
spirometry-confirmed COPD diagnosis
Of the 648 patients for whom pulmonary function test results 
were available, 282 could be classified either as having 
  normal spirometry (FEV1/forced vital capacity [FVC] $0.7 
and percentage of predicted FEV1 $ 80%) or as being 
“restricted” (FEV1/FVC $ 0.7 and percentage of predicted 
FEV1 , 80%). At the time of spirometry-confirmed COPD 
diagnosis, the majority of the remaining 366 patients with 
GOLD stage I or higher were assigned a GOLD stage reflect-
ing moderate, severe, or very severe disease (Figures 1 and 2). 
Stage II (moderate) disease was present in 50% of patients; 
stage III (severe) disease in 26%; and stage IV (very severe) 
in 5% (Figure 1).
Demographics and comorbidities  
by severity at initial spirometry-confirmed 
COPD diagnosis
Table 2 shows demographics and comorbidities for all 
648 patients for whom pulmonary function test results were 
available. Among the 366 patients with COPD of GOLD 
stage I or higher, the majority of patients were $65 years 
of age at the time of diagnosis, and mean age at diagnosis 
was similar across the severity groups. The majority of 
patients with GOLD stage I (mild) disease at diagnosis were 
male (81.7%), whereas males accounted for the minority 
of patients with GOLD stage II (moderate), III (severe), 
or IV (very severe) disease. The likelihood of being 
underweight increased with increasing COPD severity; 
15.8% of patients with GOLD stage IV (very severe) disease 
were underweight. The mean number of cigarette pack years 
was greater for those with GOLD stage III (severe) or IV 
(very severe) disease than for those with less severe disease, 
and those with GOLD stage III or IV disease were more 
likely than those with less severe disease to be smoking at 
the time of diagnosis.
Of the comorbidities assessed, asthma and cardiovascular 
disease (dyslipidemia, angina, congestive heart disease, 
evidence of cardiac stents, coronary artery bypass graft, 
ischemic heart disease, other cardiac conditions defined) were 
the most common. An asthma-related claim during the year 
prior to COPD diagnosis was found in 23% of patients with International Journal of COPD 2011:6
Table 2 Demographics and baseline characteristics from medical charts for 648 Lovelace members including patients with COPD   
(n = 366; Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition) at initial pulmonary function test
Variable Normal  
spirometry  
(n = 138)
Restricted 
spirometry  
(n = 144)
GOLD stage I,  
mild  
(n = 71)
GOLD stage II,  
moderate  
(n = 180)
GOLD stage III,  
severe  
(n = 96)
GOLD stage IV,   
very severe  
(n = 19)
Mean age [years (sD)] 71(12.7) 68 (21.8) 73 (10.7) 71 (9.5) 69 (9.8) 66 (15.0)
Age group [n (%)]
 , 40 years 2 (1.4) 4 (2.8) 0 (0) 0 (0) 1 (1.0) 1 (5.3)
  40–49 years 9 (6.5) 14 (9.7) 3 (4.2) 4 (2.2) 1 (1.0) 2 (10.5)
  50–64 years 29 (21.0) 34 (23.6) 12 (16.9) 37 (20.6) 26 (27.1) 3 (15.8)
 $ 65 years 98 (71.0) 92 (63.9) 56 (79.8) 139 (77.2) 68 (70.8) 13 (68.4)
sex [n (%)]
  Male 81 (58.7) 41 (28.5) 58 (81.7) 77 (42.8) 29 (30.2) 7 (36.8)
  Female 57 (41.3) 103 (71.5) 13 (18.3) 103 (57.2) 67 (69.8) 12 (63.2)
Weight status* [n (%)]
  Underweight 1 (0.7) 5 (3.5) 0 (0.0) 6 (3.3) 7 (7.3) 3 (15.8)
  normal weight 49 (35.5) 30 (20.8) 25 (35.2) 52 (28.9) 39 (40.6) 10 (52.6)
  Overweight 46 (33.3) 39 (27.1) 32 (45.1) 72 (40.0) 32 (33.3) 3 (15.8)
  Obese 44 (31.9) 72 (50.0) 14 (19.7) 53 (29.4) 20 (20.8) 3 (15.8)
Mean BMI [kg/m2 (sD)] 27.7 (4.9) 30.7 (8.1) 26.9 (3.8) 28.40 (7.0) 26.4 (6.4) 23.1 (5.4)
Current smoker [n (%)] 24 (17.4) 31 (21.5) 12 (16.9) 38 (21.1) 25 (26.0) 5 (26.3)
Mean cigarette pack years (sD) 23 (26.7) 25.4 (26.6) 36.6 (21.9) 36.1 (25.4) 40.0 (26.9) 47.7 (32.2)
Note: *Underweight, 16.5–18.4 kg/m2; normal weight, 18.5–24.9 kg/m2; overweight, 25–30 kg/m2; obese, $30.1 kg/m2. 
Abbreviations: BMI, body mass index; sD, standard deviation.
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GOLD stage I (mild) disease, 43% of patients with GOLD 
stage II (moderate) disease, and 42% of patients with GOLD 
stage III (severe) or IV (very severe) disease (Figure 3). The 
frequency of cardiovascular disease ranged from 13% to 
21% across severity groups. The frequencies of the other 
comorbidities assessed were too low in each severity group 
to permit conclusions.
Medications
As Figure 4 shows, at the time of initial spirometry-
confirmed COPD diagnosis among the 366 patients with 
GOLD stage I disease, less than half of patients across 
severity categories and only 43% of those with GOLD stage 
III (severe) or IV (very severe) disease were prescribed a 
maintenance therapy for COPD. Patients with GOLD stage 
III (severe) or IV (very severe) disease were more likely 
to be   prescribed maintenance therapy at initial diagnosis 
compared with patients with milder forms of the disease. 
Likewise, patients with GOLD stage III (severe) or IV 
(very severe) disease were more likely to be prescribed a 
rescue medication. The frequency of being prescribed oral 
corticosteroids or antibiotics was similar across severity 
groups.
Table 3 shows the frequency of pharmacy claims for 
maintenance and rescue medications during the year after 
the index pulmonary function for all 648 patients for whom 
pulmonary function tests were available. Less than 30% 
of those with spirometry-confirmed diagnosis of mild or 
moderate COPD received maintenance treatment, and less 
than 50% of those with spirometry-confirmed diagnosis 
of severe or very severe disease received maintenance 
treatment. 
Discussion
In this study, COPD severity was characterized at the 
time of initial diagnosis as confirmed by spirometry by 
examining medical charts for patients with COPD who were 
continuously enrolled in a closed-network HMO setting. 
Longitudinal administrative claims data and medical chart 
data were linked in the Lovelace Health Plan. While claims 
data are usually very robust and reliable, the potential exists 
for misclassification or coding error. Misclassification errors 
are a limitation in any survey of COPD patients. The GOLD 
guidelines specifically mention asthma, congestive heart fail-
ure, bronchiectasis, tuberculosis, obliterative bronchiolitis, 
and diffuse panbronchiolitis in the differential diagnosis of 
COPD. In the current study, severity at initial spirometry-
confirmed COPD was documented and post-bronchodilator 
spirometry values were used to categorize patients into 
  severity stages using GOLD classifications. This approach 
avoided the limitation, common to many observational 
studies that use ICD-9-CM codes to identify COPD patients 
within claims, of lack of objective spirometric confirmation 
of COPD diagnosis. In the large US managed care population International Journal of COPD 2011:6
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Figure 3 Proportion of patients with selected comorbidities by disease severity. 
Abbreviation: gOLD, global Initiative for Chronic Obstructive Lung Disease.
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Figure 4 Proportion of patients prescribed COPD-related medications at initial diagnosis. 
Notes: Maintenance treatment included anticholinergics, inhaled corticosteroids, long-acting beta agonists, or the combination of an inhaled corticosteroid and a long-acting 
beta agonist; rescue therapy was albuterol. 
Abbreviation: gOLD, global Initiative for Chronic Obstructive Lung Disease.
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assessed in the current study, a minority of patients with 
COPD were diagnosed at the stage of mild disease: only 
19% of patients with an initial diagnosis between 1994 and 
2006 had mild COPD (GOLD stage I) based on spirometry 
at the time of diagnosis. One in three patients (31%) with 
an initial diagnosis based on spirometry had severe or very 
severe disease (GOLD stage III or IV , respectively) at the 
time of diagnosis. The results suggest that COPD severity is 
underestimated, with a resultant delay in diagnosis, and they 
provide objective data that support the recommendation for 
screening programs that can detect COPD at earlier stages 
of the disease.2,13International Journal of COPD 2011:6
Table 3 Frequency of pharmacy use over 1 year post index for 648 COPD patients by global Initiative for Chronic Obstructive Lung 
Disease (gOLD) stage
Variable Normal  
spirometry 
[n (%)]
Restricted  
spirometry 
[n (%)]
GOLD stage I,  
mild 
[n (%)]
GOLD stage II,  
moderate 
[n (%)]
GOLD stage III,  
severe 
[n (%)]
GOLD stage IV, 
very severe 
[n (%)]
Total number of patients 138 (100.0) 144 (100.0) 71 (100.0) 180 (100.0) 96 (100.0) 19 (100.0)
no treatment* 98 (71) 89 (61.8) 40 (56.3) 103 (57.2) 44 (45.8) 11 (57.9)
Antibiotic/oral corticosteroid 31 (22.5) 48 (33.3) 24 (33.8) 49 (27.2) 33 (34.4) 4 (21.1)
Maintenance treatment† 21 (15.2) 23 (16.0) 20 (28.2) 48 (26.7) 42 (43.8) 8 (42.1)
rescue therapy‡ 10 (7.2) 19 (13.2) 8 (11.3) 28 (15.6) 35 (36.5) 4 (21.1)
Notes: *Patients may use drugs from multiple categories: percentages shown are not additive for antibiotic/oral corticosteroid, maintenance treatment, or rescue therapy; 
†fluticasone propionate/salmeterol xinafoate combination, ipratropium, tiotropium, long-acting beta agonist, inhaled corticosteroid; ‡short-acting beta agonist or nebulized 
short-acting beta agonist.
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One of the most important findings of this study was that 
patients with COPD of GOLD stage I or higher (n = 366) 
had an average percentage of predicted FEV1 of 60% at the 
time of initial spirometry. That the percentage of predicted 
FEV1 values reflected borderline severe disease at the time 
of initial diagnosis reflects a significant delay in recognition 
of COPD. Many (76%) of the 366 patients with COPD of 
GOLD stage I or higher had medical claims with COPD 
ICD-9-CM codes in the period preceding their initial COPD-
confirming pulmonary function test, and most of the medical 
encounters occurred in the primary care setting. This pattern 
of findings suggests that COPD is rarely confirmed using 
spirometry in primary care and is consistent with the pre-
vious observation that only 30%–50% of newly diagnosed 
patients have their diagnosis confirmed by spirometry.13 
The results of this study, which is to the authors’ knowl-
edge among the first to quantify the delayed diagnosis of 
COPD, are consistent with perceptions of the progressive 
nature of undiagnosed COPD and they underscore the need 
for improvement in the diagnosis and management of this 
chronic progressive disease.
At this time, effective early detection methods for COPD 
are still in development. Spirometry is necessary to confirm 
a diagnosis of COPD. However, the cost and logistics of 
spirometry render it impractical as a population-based 
screening tool in many health care settings.14 Alternatives 
to spirometry are needed to screen patients for COPD. 
Several tools to screen for COPD have been developed.15–22 
For example, the five-item Lung Function Questionnaire, 
designed to identify patients appropriate for spirometry-
confirmed diagnostic evaluation for COPD, has recently 
been validated.15,16 This instrument is suitable for use in both 
primary and specialist care.
Males accounted for the majority of patients with GOLD 
stage I (mild) disease at diagnosis and for the minority 
of patients with GOLD stage II (moderate), III (severe), 
or IV (very severe) disease. The basis for the difference in 
sex distribution by severity at diagnosis is unknown. In a 
systematic review and meta-analysis of studies conducted 
in 28 countries from 1990 to 2004, the prevalence rate of 
COPD (GOLD stage I and higher) was higher in men than 
in women.23 In the US, the incidence of COPD is growing 
faster among women, although the most recent surveys 
suggest the prevalence rate is still higher in men.1 The late 
presentation of COPD in this population could reflect the 
traditional perception among clinicians that COPD is a 
man’s disease. The possible influence of gender on severity 
at diagnosis warrants additional study in other health care 
settings.
Comorbidities can affect the severity of COPD and 
its overall impact on the patient; therefore, comorbidities 
should influence therapeutic management.1 Patients with 
COPD are at heightened risk for myocardial infarction, 
angina, osteoporosis, respiratory infection, bone fractures, 
depression, and diabetes.1 COPD may contribute to some 
of these comorbidities via its extrapulmonary effects such 
as malnutrition and skeletal muscle dysfunction.1 In the 
current study, asthma and cardiovascular disease were the 
most prevalent comorbidities – a result consistent with 
previous findings.1,24 While the incidence of asthma was 
particularly high in patients with moderate or more severe 
COPD, more than 40% of whom had asthma, it was also 
common among patients with mild COPD, 23% of whom 
had asthma. These findings underscore the importance 
of assessing patients with COPD for other respiratory 
comorbidities, particularly asthma, regardless of COPD 
severity.
The results of this study should be interpreted in the con-
text of its limitations. First, records of more than half of the 
1520 patients with evidence of pulmonary function tests or a 
pulmonary clinic visit were excluded from the evaluation for 
COPD diagnosis and severity staging because of insufficient International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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pulmonary chart data (due to issues with archiving and stor-
age). Exclusion of these records might have resulted in selec-
tion bias if the excluded records differed systematically in some 
way from the records that were included. Another limitation 
of the study is possible lack of generalizability of the results 
from the Lovelace Health Plan, a closed-network HMO plan, 
to other commercial health plans prevalent in the US. 
Conclusion
The results of this study demonstrate a very low incidence 
of early-stage spirometry-confirmed diagnosis of COPD in a 
large US sample and they support calls for increased screen-
ing for COPD.13 The majority of these patients with COPD of 
GOLD stage I or higher were moderate to severe, as defined 
by GOLD guidelines. This study found that a substantial 
number of patients without prior history of spirometry had 
already progressed to advanced stages of disease. Further-
more, once diagnosed using spirometry, a low proportion of 
patients received maintenance treatment, revealing a possible 
opportunity to improve care.
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